REQUEST A DEMO
Total
USD $0.00
Search more companies

Tanvex BioPharma, Inc. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing | Research and Development in the Physical, Engineering, and Life Sciences
Full name: Tanvex BioPharma, Inc. Profile Updated: May 26, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Tanvex BioPharma, Inc. specializes in the research, development, and sales of bio-pharmaceuticals. The company researches on the followings: cell culture, microbial and mammalian cell line development, protein purification and pharmaceuticals. Tanvex BioPharma, Inc. was established in 1984 and main company is located in New Taipei City.

Headquarters
Rm. 1, 13F., No.376, Sec. 4, Ren'Ai Rd., Da'An Dist
Taipei City; Taipei City;

Contact Details: Purchase the Tanvex BioPharma, Inc. report to view the information.

Website: http://www.tanvex.com

Basic Information
Total Employees:
Purchase the Tanvex BioPharma, Inc. report to view the information.
Outstanding Shares:
Purchase the Tanvex BioPharma, Inc. report to view the information.
Financial Auditors:
Purchase the Tanvex BioPharma, Inc. report to view the information.
Incorporation Date:
May 08, 2013
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
17.61%
Purchase this report to view the information.
6.36%
Purchase this report to view the information.
3.59%
Purchase this report to view the information.
0.65%
Purchase this report to view the information.
0.09%
Subsidiaries
Tanvex Biopharma Usa, Inc
100%
台灣泰福生技股份有限公司
100%
Company Performance
Financial values in the chart are available after Tanvex BioPharma, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
-56.87%
Total operating revenue
-56.04%
Operating profit (EBIT)
28.7%
EBITDA
31.93%
Net Profit (Loss) for the Period
29.53%
Total assets
-9.46%
Total equity
-17.47%
Operating Profit Margin (ROS)
-1522.57%
Net Profit Margin
-1495.41%
Return on Equity (ROE)
9.09%
Quick Ratio
-1.34%
Cash Ratio
-1.53%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?